Short answer
Solventum (SOLV) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $2.0B (down 3.0% year over year) with net income of $13M.
Q1 2026 key financials · XBRL
- Revenue
- $2.0B
- −3.0% YoY
- Net income
- $13M
- −90.5% YoY
- Operating margin
- 4.0%
- Gross margin
- 54.7%
- EPS (diluted)
- $0.07
- −91.0% YoY
Source: XBRL data from the Solventum (SOLV) Q1 2026 10-Q on SEC EDGAR. USD.
Solventum Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $2,007M, down 3.0% YoY from $2,070M, reflecting Purification and Filtration divestiture
- Operating margin 4.0% vs 7.3% YoY; effective tax rate 19.3% vs (262.1)%
- Best segment Health Information Systems: sales $342M, up 4.1%; margin 38.1% vs 33.1%
- Worst segment MedSurg: operating income $161M, down 21.8%; margin 13.1% vs 17.8%
- Cash $561M vs $878M; operating cash flow $(189)M vs $29M; share repurchases $67M
- Near-term headwinds: tariffs, inflation, changing market conditions, and uncertain tariff-refund timing
Risk Factors
- No material changes to 2025 10-K risk factors
- No newly added risk factor identified for the quarter
- No material regulatory, legal, or compliance risk updates disclosed
- No operational, competitive, or market risk updates disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Solventum quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.